Fig. 1.

Depletion of DRG2 inhibits HeLa cell proliferation. (A) Knock-down efficiency of the sh-DRG2 cells. (B) Cell proliferation was determined by cell counting. Data are means ± S.E. of three independent experiments (^** p < 0.01; ^*** p < 0.001). (C) Cells were incubated with [³H]-thymidine for 20 hours and the incorporated tritium was measured with a beta counter. Data are means ± S.E. of three independent experiments. (D) Number of BrdU positive cells was reduced in sh-DRG2 cells. Data are presented as the mean ± S.E. (^*p < 0.05) (Green; BrdU, Blue; DAPI, Scale bar; 10 μm). (E) Cell migration was assessed by a wound healing assay using silicon inserts. The dashed line represents time zero, and the denuded area is gradually closed by cell migration. (F) Suppression of in vivo tumor development by DRG2 deficiency. Control and sh-DRG2 cells were injected subcutaneously into BALB/c nude mice (n = 4 for each group). Data present mean ± S.E. of two independent experiments. Photographs of representative mice were taken 8 weeks after injection. See “Materials and Methods” for further details.